IDYA.US Ideaya Biosciences Inc

Healthcare Biotechnology USA Stocks
31.83 USD
Close of Nov 15, 2026
26.81 42.68
Market cap
USD 3.08B
P/E
-
P/B
2.82x
ROE
-41.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IDYA.US undervalued?

Graham number

The Graham number of Ideaya Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ideaya Biosciences Inc fundamental analysis

No fundamental analysis for Ideaya Biosciences Inc yet.

Ideaya Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ideaya Biosciences Inc

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant setting…

Full company profile